6-(3-hydroxyphenyl)-1-(1-methyl-1H-pyrazol-4-yl)-2-naphthol | 1262388-19-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-(3-hydroxyphenyl)-1-(1-methyl-1H-pyrazol-4-yl)-2-naphthol
• 英文别名: 6-(3-Hydroxyphenyl)-1-(1-methylpyrazol-4-yl)naphthalen-2-ol
• CAS: 1262388-19-1
• 化学式: C₂₀H₁₆N₂O₂
• 分子量: 316.359
• InChiKey: FWEYEXQGPATDLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  58.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-溴-2-甲氧基-6-(3-甲氧基苯基)萘 在 四(三苯基膦)钯 、 三溴化硼 、 caesium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 二氯甲烷 、 水 为溶剂， -78.0~150.0 ℃ 、1.5 MPa 条件下， 反应 0.42h， 生成 6-(3-hydroxyphenyl)-1-(1-methyl-1H-pyrazol-4-yl)-2-naphthol
  参考文献：
  名称：

  New Drug-Like Hydroxyphenylnaphthol Steroidomimetics As Potent and Selective 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Estrogen-Dependent Diseases

  摘要：

  Inhibition of 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1) is a novel and attractive approach to reduce the local levels of the active estrogen 17 beta-estradiol in patients with estrogen-dependent diseases like breast cancer or endometriosis. With the aim of optimizing the biological profile of 17 beta-HSD1 inhibitors from the hydroxyphenylnaphthol class, structural optimizations were performed at the 1-position of the naphthalene by introduction of different heteroaromatic rings as well as substituted phenyl groups. In the latter class of compounds, which were synthesized applying Suzuki-cross coupling, the 3-methane-sulfonamide 15 turned out to be a highly potent 17 beta-HSD1 inhibitor (IC50 = 15 nM in a cell-free assay). It was also very active in the cellular assay (T47D cells, IC50 = 71 nM) and selective toward 17 beta-HSD2 and the estrogen receptors alpha and beta. It showed a good membrane permeation and metabolic stability and was orally available in the rat.

  DOI：

  10.1021/jm1009082

文献信息

• New Drug-Like Hydroxyphenylnaphthol Steroidomimetics As Potent and Selective 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Estrogen-Dependent Diseases
  作者：Sandrine Marchais-Oberwinkler、Marie Wetzel、Erika Ziegler、Patricia Kruchten、Ruth Werth、Claudia Henn、Rolf W. Hartmann、Martin Frotscher

  DOI：10.1021/jm1009082

  日期：2011.1.27

  Inhibition of 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1) is a novel and attractive approach to reduce the local levels of the active estrogen 17 beta-estradiol in patients with estrogen-dependent diseases like breast cancer or endometriosis. With the aim of optimizing the biological profile of 17 beta-HSD1 inhibitors from the hydroxyphenylnaphthol class, structural optimizations were performed at the 1-position of the naphthalene by introduction of different heteroaromatic rings as well as substituted phenyl groups. In the latter class of compounds, which were synthesized applying Suzuki-cross coupling, the 3-methane-sulfonamide 15 turned out to be a highly potent 17 beta-HSD1 inhibitor (IC50 = 15 nM in a cell-free assay). It was also very active in the cellular assay (T47D cells, IC50 = 71 nM) and selective toward 17 beta-HSD2 and the estrogen receptors alpha and beta. It showed a good membrane permeation and metabolic stability and was orally available in the rat.